Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial

Muscle and Nerve

Volumn 56, Issue 5, 2017, Pages 901-911

  Dyck, Peter J ^a   Kincaid, John C ^b   Dyck, P James B ^a   Chaudhry, Vinay ^c   Goyal, Namita A ^d   Alves, Christina ^e   Salhi, Hayet ^f   Wiesman, Janice F ^g   Labeyrie, Celine ^h   Robinson Papp, Jessica ⁱ   Cardoso, Márcio ^e   Laura, Matilde ^j   Ruzhansky, Katherine ^k   Cortese, Andrea ^l   Brannagan, Thomas H ^m   Khoury, Julie ⁿ   Khella, Sami ^o   Waddington Cruz, Márcia ^p   Ferreira, João ^q   Wang, Annabel K ^d   Pinto, Marcus V ^p   Ayache, Samar S ^f   Benson, Merrill D ^r   Berk, John L ^s   Coelho, Teresa ^e   Polydefkis, Michael ^c   Gorevic, Peter ⁱ   Adams, David H ^h   Plante Bordeneuve, Violaine ^f   Whelan, Carol ^j   Merlini, Giampaolo ^t   Heitner, Stephen ⁿ   Drachman, Brian M ^o   Conceição, Isabel ^q   Klein, Christopher J ^a   Gertz, Morie A ^a   Ackermann, Elizabeth J ^u   Hughes, Steven G ^u   Mauermann, Michelle L ^a   Bergemann, Rito ^v   Lodermeier, Karen A ^a   Davies, Jenny L ^a   Carter, Rickey E ^a   Litchy, William J ^a   more..

^a MAYO CLINIC   (United States)

^b INDIANA UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^f HENRI MONDOR HOSPITAL   (France)

^g BOSTON MEDICAL CENTER   (United States)

^h BICÊTRE HOSPITAL   (France)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^m Och Spine at New York Presbyterian Hospitals   (United States)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^p FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^q UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^r INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t UNIVERSITY OF PAVIA   (Italy)

^u ISIS PHARMACEUTICALS   (United States)

^v GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

disability; familial amyloidotic polyneuropathy (FAP); neurophysiologic tests; oligonucleotide trials; peripheral neuropathy; polyneuropathy signs; proficiency

Indexed keywords

IONIS TTRRX; PATISIRAN; OLIGONUCLEOTIDE;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DISABILITY; DISEASE SEVERITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HEALTH STATUS; HEAT SENSATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; NERVE FIBER; NEUROLOGIST; NEUROPATHY IMPAIRMENT SCORE; NEUROPHYSIOLOGY; NOCICEPTION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; AMYLOID NEUROPATHIES, FAMILIAL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; INTERNATIONAL COOPERATION; MIDDLE AGED; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; COHORT STUDIES; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; DISABILITY EVALUATION; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGISTS; OLIGONUCLEOTIDES; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX;

EID: 85017437175     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25563     Document Type: Article

References (39)

1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
2. Andrade C. A peculiar form of peripheral neuropathy. Brain 1952;75:408–427.
3. Blake CC, Geisow MJ, Oatley SJ, Rerat B, Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978;121:339–356.
4. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654–8660.
5. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995;268:1039–1041.
6. Plante-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998;51:708–714.
7. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411–423.
8. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274:1637–1650.
9. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem 2012;19:2324–2342.
10. Saraiva MJ, Magalhaes J, Ferreira N, Almeida MR. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem 2012;19:2304–2311.
11. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31.
12. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts 2014;5:45–54.
13. Said G, Ropert A, Faux N. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology 1984;34:1025–1032.
14. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658–2667.
15. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63–76.
16. Dohrn MF, Rocken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013;260:3093–3108.
17. Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci 2014;344:121–128.
18. Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology 2015;85:675–682.
19. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274:702–706.
20. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–792.
21. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl 2009;15:1229–1235.
22. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242–246.
23. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013;47:157–162.
24. Alnylam Pharmaceuticals. A phase 3 multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ALN-TTR02 in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy—FAP). Available at http://clinicaltrials.gov/ct2/show/NCT01960348. Accessed August 25, 2015.
25. Ionis Pharmaceuticals. A phase 2/3 randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of ISIS 420915 in patients with familial amyloid polyneuropathy. Available at http://clinicaltrials.gov/ct2/show/NCT01737398. ClinicalTrialsgov. Accessed January 24, 2017.
26. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621–637.
27. Dyck PJ, Taylor BV, Davies JL, Mauermann ML, Litchy WJ, Klein CJ. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Muscle Nerve 2015;52:488–497.
28. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482–1486.
29. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817–824.
30. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590–596.
31. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of healthy subjects (RDNS-HS). Neurology 1995;45:1115–1121.
32. Dyck PJ, Herrmann DN, Staff NP, Dyck PJB. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes 2013;62:3677–3686.
33. Dyck PJ, Argyros B, Russell JW, et al. Multicenter trial of the proficiency of smart quantitative sensation tests. Muscle Nerve 2014;49:645–653.
34. Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJ, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys Trial. Muscle Nerve 2010;42:157–164.
35. Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJ, et al. “Unequivocally abnormal” vs. “usual” signs and symptoms for proficient diagnosis of diabetic polyneuropathy Cl vs. N Phys Trial. Arch Neurol 2012;69:1609–1614.
36. Dyck PJ, Turner DW, Davies JL, O'Brien PC, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci 2002;29:258–266.
37. O'Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995;45:17–23.
38. Dyck PJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve 2013;48:369–374.
39. Litchy WJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. Proficiency of nerve conduction using standard methods and reference values. Muscle Nerve 2014;50:900–908.